RxDoctor Payments Data

Harikrishnan Damodaran-Nair, MD

Interventional Cardiology · Glasgow, KYNPI 1871608125

Payments from drug & device makers

$2,268in general payments, 2019–2025

Across 135 payments — averaging $16.80 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$698
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$423
  • Pfizer$194
  • AstraZeneca$156
  • Novartis$139
  • Amgen$139
  • plus $518 from 9 others

What the payments were for

  • Food & beverage$1,98688%
  • Education$28112%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$2,268 in reported general payments places this provider in the 15th percentile of 129 interventional cardiology providers in Kentucky.

See all interventional cardiology providers in Kentucky

Medicare billing

Part B allowed, 2024
$337,547
Medicare patients
1,775
Services billed
6,122

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban849$681,106
XareltoRivaroxaban162$147,757
BrilintaTicagrelor176$106,461
Ranolazine ErRanolazine1,482$78,315
EntrestoSacubitril/Valsartan94$75,867
Prasugrel Hcl673$59,668
VascepaIcosapent Ethyl104$53,734
Repatha SyringeEvolocumab35$26,610
Repatha SureclickEvolocumab30$17,307
Praluent PenAlirocumab25$14,225
Atorvastatin Calcium1,780$11,819
Metoprolol Succinate1,026$9,163
Potassium Chloride645$9,115
Midodrine Hcl75$7,915
Diltiazem Hcl280$7,452

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$194$681,106849 claims
Johnson & JohnsonXarelto$698$147,757162 claims
AstraZenecaBrilinta, Farxiga$156$112,637188 claims
NovartisEntresto$139$75,86794 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 15th percentile of 129 interventional cardiology providers in Kentucky.

Other interventional cardiology in Glasgow

See the full list for Kentucky

Where these figures come from

Is this you, or does something look wrong? →